UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2015 (September 9, 2015)
ARCA biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
000-22873 |
36-3855489 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
11080 CirclePoint Road, Suite 140, Westminster, CO 80020
(Address of Principal Executive Offices) (Zip Code)
(720) 940-2200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
£ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
£ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
£ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 8.01. |
Other Events. |
On September 9, 2015, ARCA biopharma, Inc. (“ARCA”) announced that the paper “Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism” will be presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) to be held in Washington, D.C. September 26-29, 2015. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release titled “GencaroTM Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to be Presented at 2015 HFSA Annual Scientific Meeting” dated September 9, 2015. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: September 9, 2015 |
|
||
|
|
|
||
|
|
ARCA biopharma, Inc. |
||
|
|
(Registrant) |
||
|
|
|
|
|
|
|
By: |
/s/ Christopher D. Ozeroff |
|
|
|
|
Name: |
Christopher D. Ozeroff |
|
|
|
Title: |
Senior Vice President and General Counsel |
INDEX TO EXHIBITS
|
|
|
|
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release titled “GencaroTM Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to be Presented at 2015 HFSA Annual Scientific Meeting” dated September 9, 2015.
|
|
|
|
|